Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, Ghamande S, Peltan I, Brown S, Ginde A, Steinwand A, Mohr N, Gibbs K, Hager D, Ali H, Frosch A, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Mosier J, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Rhoads J, Swan S, Johnson C, Lewis N, Ellington S, Dawood F, McMorrow M, Self W, Network F. Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza And Other Respiratory Viruses 2024, 18: e70027. PMID: 39496339, PMCID: PMC11534416, DOI: 10.1111/irv.70027.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationIn-Hospital OutcomesVaccine effectivenessMonovalent dosesAbsolute VETest-negative case-control designInvasive mechanical ventilationCOVID-19 vaccineMultivariate logistic regressionSevere COVID-19Case patientsCase-control designControl patientsMechanical ventilationUnvaccinated patientsPatientsMonovalent vaccineCOVID-19-like illnessDoseCOVID-19 vaccine effectivenessBivalent vaccineLogistic regressionAdmission dateVaccineHospital
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply